TG Therapeutics (TGTX) Scheduled to Post Earnings on Monday

TG Therapeutics (NASDAQ:TGTX) will be issuing its quarterly earnings data before the market opens on Monday, November 4th. Analysts expect the company to announce earnings of $0.04 per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.08. The firm had revenue of $73.47 million during the quarter, compared to analysts’ expectations of $65.92 million. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The company’s quarterly revenue was up 357.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.34) EPS. On average, analysts expect TG Therapeutics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

TG Therapeutics Price Performance

Shares of NASDAQ TGTX opened at $26.90 on Friday. The stock has a market capitalization of $4.16 billion, a PE ratio of 44.10 and a beta of 2.21. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83. The business has a fifty day moving average price of $23.51 and a two-hundred day moving average price of $20.01. TG Therapeutics has a fifty-two week low of $9.81 and a fifty-two week high of $26.99.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. The Goldman Sachs Group lifted their price objective on TG Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. B. Riley lifted their price target on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $49.00 price target on shares of TG Therapeutics in a research note on Wednesday, September 18th. Finally, TD Cowen initiated coverage on TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price target on the stock. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $36.33.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.